<DOC>
	<DOCNO>NCT00130884</DOCNO>
	<brief_summary>The study investigate efficacy oral levosimendan patient chronic New York Heart Association ( NYHA ) IIIb-IV heart failure ( HF ) use composite end-point evaluate patient symptom , morbidity mortality . The patient treatment least 6 month .</brief_summary>
	<brief_title>Peroral Levosimendan Chronic Heart Failure</brief_title>
	<detailed_description>The patient randomise 3 group ; high low levosimendan dose group placebo .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>Diagnosed chronic heart failure Severe symptom ( NYHA IIIbIV ) Optimal ongoing oral treatment HF Left ventricular ejection fraction less equal 30 % Severe obstruction ventricular outflow tract Acute myocardial infarction within 30 day screen Cardiac surgery coronary angioplasty within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>levosimendan</keyword>
	<keyword>chronic heart failure</keyword>
	<keyword>oral administration</keyword>
</DOC>